EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of guanylate cyclase activator on cGMP and O-2 consumption in renal hypertension-induced cardiac hypertrophy



Effect of guanylate cyclase activator on cGMP and O-2 consumption in renal hypertension-induced cardiac hypertrophy



Anesthesiology (Hagerstown) 85(3A): A534




(PDF emailed within 1 workday: $29.90)

Accession: 031086054

Download citation: RISBibTeXText



Related references

Increased Negative Metabolic Effects of cGMP in Renal Hypertension-Induced Cardiac Hypertrophy. Anesthesiology Abstracts of Scientific Papers Annual Meeting ( ): Abstract No A-618, 2002

Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 301(5): L755-L764, 2011

Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharmaceutica Acta Helvetiae 73(1): 27-35, 1998

The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. European Journal of Pharmacology 767: 1-9, 2016

Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. American Journal of Physiology Renal Physiology 292(3): P974-P980, 2007

Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. American Journal of Physiology. Renal Physiology 292(3): F974-F980, 2006

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux. Journal of Pharmacology and Experimental Therapeutics 355(1): 48-56, 2015

Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy. Research In Experimental Medicine. 1: 11-21, Y, 1998

The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 297(4): L658-L665, 2009

YC-1, a soluble guanylate cyclase activator, potentiates the NO/cGMP pathway and facilitates penile erection in rats. Journal of Urology 167(4 Supplement): 239, April, 2002

Relationship between cGMP and myocardial O2 consumption is altered in T4-induced cardiac hypertrophy. American Journal of Physiology 268(2 Pt 2): H686-H691, 1995

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib-Induced Hypertension. Journal of the American Heart Association 7(18): E009557-E009557, 2018

Hormonal regulation of the different isoforms of guanylate cyclase edrf is a ubiquitous activator of soluble guanylate cyclase. Rubanyi, G M And P M Vanhoutte (Ed ) Endothelium-Derived Relaxing Factors; First International Symposium on Endothelium-Derived Vasoactive Factors, Philadelphia, Pennsylvania, Usa, May 1-3, 1989 X+337p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 151-165, 1990

cGMP level that reduces cardiac myocyte O2 consumption is altered in renal hypertension. American Journal of Physiology. Heart and Circulatory Physiology 273(4): H1949-H1955, 1997

cGMP level that reduces cardiac myocyte O2 consumption is altered in renal hypertension. American Journal of Physiology 273(4 Pt 2): H1949-H1955, 1997